Lipitor's Mechanism on HMG-CoA Reductase
Lipitor (atorvastatin) inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, by competitively binding to its active site. It mimics HMG-CoA and occupies the substrate-binding pocket with high affinity, forming a mevalonate-like complex that blocks the enzyme's catalytic function.[1]
Specific Binding Sites of Highest Affinity
The crystal structure (PDB: 1HWK) shows atorvastatin binds primarily at the active site, with key interactions at:
- His237: Forms a hydrogen bond with the drug's hydroxy group, stabilizing the mevalonate mimic.
- Arg209: Interacts electrostatically with the carboxylate, mimicking HMG-CoA's phosphate.
- Asp690: Hydrogen bonds to the drug's fluorophenyl ring.
- Gln757 and Lys691: Contribute to hydrophobic and polar contacts in the pocket.
These residues form the highest-affinity pocket, with atorvastatin's Ki around 5-10 nM—among the tightest for statins due to its compact pyrrole core fitting snugly.[1][2]
How Lipitor Compares to Other Statins in Binding
Unlike simvastatin (prefers Lys727 more prominently), Lipitor's affinity excels at His237/Arg209 due to its rigid structure, explaining its potency (IC50 ~6 nM vs. pravastatin's 100 nM).2
Variations Across HMG-CoA Reductase Isoforms or Mutants
Human HMG-CoA reductase has no major isoforms, but gain-of-function mutants (e.g., in familial hypercholesterolemia) like Asp767→Gly reduce Lipitor affinity at the Asp690-equivalent site, requiring higher doses.3
[1]: Istvan & Deisenhofer, Science (2001)
[2]: DrugPatentWatch.com - Atorvastatin Binding Data